JP6356160B2 - ネオセプチン：低分子アジュバント - Google Patents

ネオセプチン：低分子アジュバント Download PDF

Info

Publication number
JP6356160B2
JP6356160B2 JP2015559275A JP2015559275A JP6356160B2 JP 6356160 B2 JP6356160 B2 JP 6356160B2 JP 2015559275 A JP2015559275 A JP 2015559275A JP 2015559275 A JP2015559275 A JP 2015559275A JP 6356160 B2 JP6356160 B2 JP 6356160B2
Authority
JP
Japan
Prior art keywords
mmol
etoac
group
equiv
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015559275A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513128A5 (enExample
JP2016513128A (ja
Inventor
ブルース ボイトラー
ブルース ボイトラー
デイル エル ボガー
デイル エル ボガー
Original Assignee
ザ スクリプス リサーチ インスティテュート
ザ スクリプス リサーチ インスティテュート
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム
ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート, ザ スクリプス リサーチ インスティテュート, ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム, ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ テキサス システム filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2016513128A publication Critical patent/JP2016513128A/ja
Publication of JP2016513128A5 publication Critical patent/JP2016513128A5/ja
Application granted granted Critical
Publication of JP6356160B2 publication Critical patent/JP6356160B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2015559275A 2013-02-25 2014-02-25 ネオセプチン：低分子アジュバント Expired - Fee Related JP6356160B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361768712P 2013-02-25 2013-02-25
US61/768,712 2013-02-25
PCT/US2014/018380 WO2014131023A1 (en) 2013-02-25 2014-02-25 Neoseptins: small molecule adjuvants

Publications (3)

Publication Number Publication Date
JP2016513128A JP2016513128A (ja) 2016-05-12
JP2016513128A5 JP2016513128A5 (enExample) 2017-04-06
JP6356160B2 true JP6356160B2 (ja) 2018-07-11

Family

ID=51391916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015559275A Expired - Fee Related JP6356160B2 (ja) 2013-02-25 2014-02-25 ネオセプチン：低分子アジュバント

Country Status (7)

Country Link
US (1) US9649373B2 (enExample)
EP (1) EP2958889B1 (enExample)
JP (1) JP6356160B2 (enExample)
CN (1) CN105339346B (enExample)
AU (1) AU2014218598B2 (enExample)
CA (1) CA2902342C (enExample)
WO (1) WO2014131023A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5922791B2 (ja) 2012-10-29 2016-05-24 京セラ株式会社 弾性表面波センサ
WO2016011195A1 (en) 2014-07-17 2016-01-21 Threshold Pharmaceuticals, Inc. Th-302 solid forms and methods related thereto
WO2016145092A1 (en) 2015-03-10 2016-09-15 Threshold Pharmaceuticals, Inc. Dna alkylating agents
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
US20180169064A1 (en) 2015-06-24 2018-06-21 Threshold Pharmaceuticals, Inc. Aziridine containing dna alkylating agents
WO2017083823A1 (en) * 2015-11-13 2017-05-18 Brandeis University Mtor inhibitors and methods of use thereof
BR112018077397A2 (pt) * 2016-06-29 2019-10-01 The Scripps Research Institute diprovocims: uma classe de agonistas de tlr
KR102775718B1 (ko) 2017-11-14 2025-03-06 칠드런'즈 메디컬 센터 코포레이션 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031083A (en) 1975-10-24 1977-06-21 Yeda Research And Development Co., Ltd. Cephalosporin antibiotics
US4045438A (en) 1975-10-24 1977-08-30 Yeda Research And Development Co. Ltd. Cephalosporin antibiotics
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
EP2292628A3 (en) * 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
CA2620182A1 (en) * 2005-08-22 2007-03-01 Dennis A. Carson Tlr agonists
JP2009542689A (ja) * 2006-07-07 2009-12-03 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 選択的カスパーゼ阻害剤
EP2510946B1 (en) * 2007-02-07 2015-08-05 The Regents of The University of California Conjugates of synthetic tlr agonists and uses therefor
SI2268618T1 (sl) * 2008-03-03 2015-09-30 Novartis Ag Spojine in sestavki kot modulatorji aktivnosti TLR
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト

Also Published As

Publication number Publication date
CA2902342C (en) 2017-10-17
EP2958889B1 (en) 2017-03-22
CN105339346A (zh) 2016-02-17
CN105339346B (zh) 2017-03-08
EP2958889A4 (en) 2016-07-27
US9649373B2 (en) 2017-05-16
WO2014131023A1 (en) 2014-08-28
JP2016513128A (ja) 2016-05-12
US20160000907A1 (en) 2016-01-07
AU2014218598A1 (en) 2015-09-10
AU2014218598B2 (en) 2016-08-04
EP2958889A1 (en) 2015-12-30
CA2902342A1 (en) 2014-08-28

Similar Documents

Publication Publication Date Title
JP2016513128A (ja) ネオセプチン：低分子アジュバント
EP1408986B1 (en) Proteomimetic compounds and methods
TWI636044B (zh) 芳基二氫吡啶酮及六氫吡啶酮ｍｇａｔ２抑制劑
CN112312910A (zh) 人整合素α4β7拮抗剂
CN110494141A (zh) 含有被取代的多环性吡啶酮衍生物及其前药的药物组合物
CN111032034A (zh) 螺环化合物及其制造和使用方法
KR20140014399A (ko) 사람 면역결핍 바이러스 복제 억제제
CN105530923A (zh) 芳基醚及其用途
CN108884058B (zh) 大环广谱抗生素
CN105339350B (zh) 二氢吡啶酮mgat2抑制剂
JP2016518317A (ja) 二環式鎮痛化合物
CN106061968A (zh) 四唑酮‑取代的二氢吡啶酮mgat2抑制剂
CN105492075B (zh) 病毒复制抑制剂、它们的制备方法和它们的治疗用途
CN114230512A (zh) 芳香乙烯类化合物、其制备方法、中间体、药物组合物及其应用
KR20180037947A (ko) 글리코피로늄 지방산 염 및 이의 제조방법
JP2017530943A (ja) Ｔｌｒ非依存性低分子アジュバント
WO2025026209A1 (zh) Arf1抑制剂及其应用
WO2024141011A1 (zh) 补体因子b抑制剂及其药物组合物和应用
JP2018528231A (ja) Ｈｉｖ成熟阻害活性を有する化合物
JP7805369B2 (ja) 複合体ｉの制御剤
CN116284215A (zh) 一种ezh2配体protac衍生物及其制备方法和用途
WO2026032253A1 (zh) 环肽类似物及其制备方法和用途
CN118076592A (zh) Shp2抑制剂、包含其的药物组合物及其用途
WO2011150682A1 (zh) 4-羟基喹啉-3-酰胺衍生物及其制备方法和用途
JP2022527999A (ja) スフィンゴシン１リン酸受容体調節因子

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170224

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20170224

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180416

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180613

R150 Certificate of patent or registration of utility model

Ref document number: 6356160

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees